Rodolphe Jean Poussot's most recent trade in West Pharmaceutical Services, Inc. was a trade of 1,040 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| West Pharma Services | Rodolphe Jean Poussot | SVP, Strategy & Corporate Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 1,040 | 1,040 | - | - | Stock Option (Right to Buy) | |
| West Pharma Services | Rodolphe Jean Poussot | SVP, Strategy & Corporate Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 437 | 437 | - | - | Rst. Stock Unit | |
| West Pharma Services | Rodolphe Jean Poussot | SVP, Strategy & Corporate Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2026 | 383 | 383 | - | - | Rst. Stock Unit | |
| West Pharma Services | Rodolphe Jean Poussot | SVP, Strategy & Corporate Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2026 | 383 | 690 (0%) | 0% | - | Common Stock | |
| West Pharma Services | Rodolphe Jean Poussot | SVP, Strategy & Corporate Dev | Payment of exercise price or tax liability using portion of securities received from the company at price $ 242.14 per share. | 20 Feb 2026 | 129 | 561 (0%) | 0% | 242.1 | 31,236 | Common Stock |
| West Pharma Services | Rodolphe Jean Poussot | SVP, Strategy & Corporate Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 82 | 335 (0%) | 0% | - | Common Stock | |
| West Pharma Services | Rodolphe Jean Poussot | SVP, Strategy & Corporate Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 82 | 247 | - | - | Rst. Stock Unit | |
| West Pharma Services | Rodolphe Jean Poussot | SVP, Strategy & Corporate Dev | Payment of exercise price or tax liability using portion of securities received from the company at price $ 255.70 per share. | 18 Feb 2026 | 27 | 307 (0%) | 0% | 255.7 | 6,904 | Common Stock |